Page 1 of 2511234567...Last »

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide.

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide. by Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, Jr. and DiGiandomenico A published in J. Infect. Dis. 2016; 213 (4): 640-648

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. by Sanchis M, Capilla J, Castanheira M, Martin-Vicente A, Sutton DA, Fothergill AW, Wiederhold NP and Guarro J published in Int. J. Antimicrob. Agents. 2016; 47 (4): 286-288

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. by Sanchez EH, Mendes RE, Sader HS and Allison GM published in J. Antimicrob. Chemother. 2016; 71 (6): 1736-1738

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). by Sader HS, Mendes RE, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 76-79

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014.

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014. by Sader HS, Castanheira M, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4355-4360

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014.

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014. by Sader HS, Castanheira M, Flamm RK, Huband MD and Jones RN published in Surg. Infect. (Larchmt). 2016; 17 (4): 473-478

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014).

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN published in Int. J. Antimicrob. Agents. 2016; 48 (2): 144-150

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. by Pfaller MA, Messer SA, Rhomberg PR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2016; 71 (10): 2868-2873

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014.

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. by Pfaller MA, Flamm RK, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5393-5399

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model. by Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2075-2080

Page 1 of 2511234567...Last »